Publications by authors named "Pilar Diaz-Ruiz"
Article Synopsis
- MS is a significant cause of disability in young and middle-aged adults; existing clinical markers are not sensitive or specific enough for diagnosing and monitoring the disease.
- After neuronal injury in MS, neurofilament light chains (NfL) are released into the cerebrospinal fluid and blood, suggesting they may serve as a useful biomarker for monitoring inflammation and neurodegeneration.
- A study in Spain showed that blood-based NfL could improve diagnosis and treatment responses in MS, offering a safer and potentially less expensive alternative in clinical practice.
Unlabelled: Multiple sclerosis is a chronic demyelinating disease of the central nervous system and long-term disabling. Different disease-modifying treatments are available. These patients, despite being generally young, have high comorbidity and risk of polymedication due to their complex symptomatology and disability.
View Article and Find Full Text PDFUnlabelled: Multiple sclerosis is a chronic demyelinating disease of the central nervous system and long-term disabling. Different disease-modifying treatments are available. These patients, despite being generally young, have high comorbidity and risk of polymedication due to their complex symptomatology and disability.
View Article and Find Full Text PDFObjective: To compare patient experience in a real-life population of people living with HIV (PLWH) who received pharmaceutical care (PC) based on the Capacity-Motivation-Opportunity (CMO) model versus the traditional model.
Methods: Prospective cohort study in PLWH receiving either CMO-based PC or traditional PC in Spain between October 2019 and June 2021 (24 weeks), performed by the pharmacy department of 14 Spanish hospitals. Participants were adult patients with a clinical diagnosis of HIV treated with antiretrovirals who had been monitored in the participating hospital pharmacies for >1 year.
Objective: Dual PEGylated interferon-α (PEG-IFN) and ribavirin therapy has been the main hepatitis C virus (HCV) treatment of the last decade. Current direct-acting antiviral agents have improved the outcome of therapy but also have increased the cost and management complexity of treatment. The current study analyzes host genetics, viral and clinical predictors of sustained viral response (SVR) to dual PEG-IFN and ribavirin therapy in a representative Spanish population.
View Article and Find Full Text PDF